Crow Point Partners’s Lipocine LPCN Stock Holding History

Crow Point Partners’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-377	Closed	-$23K	–	273
2017 Q4	$23K	Buy	+377	New	+$23.4K	﹤0.01%	241

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Crow Point Partners's LPCN Position: Q1 2018 in Review

Crow Point Partners sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 377 shares — an estimated $23K sold.

Crow Point Partners first reported a position in LPCN in Q4 2017 and held it in 1 quarter. The position peaked at $23K in Q4 2017. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

Crow Point Partners reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
Crow Point Partners sold 377 Lipocine shares in Q1 2018, an estimated $23K.
Crow Point Partners first reported a position in Lipocine in Q4 2017 and held it in 1 quarter.
Crow Point Partners's Lipocine position peaked at $23K in Q4 2017.
27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on Crow Point Partners's 13F filing for Q1 2018, filed 10 Apr 2018.